Qinghua Wang

9PUBLICATIONS
6CO-AUTHORS
Electrochemical energy storage and conversionLiquid biopsiesMetabolic medicineExercise physiologyEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 08, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).

|Feb 11, 2026
Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double-blind, placebo-controlled trial (LIGHT 2).

Weiping Jia, Qinghua Wang

|Jan 20, 2026
Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.

Yahao Wang, Zhihong Wang, Guirui Yan

|Jan 06, 2026
Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial.

Fei Gao, Mingxia Yuan, Nianrong Mi

|Nov 10, 2025
Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial.

Rui Sun, Ying Wang, Hongyan Shu

|Sep 22, 2025
Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.

Weiping Jia, Fan Jiang, Yulong Xu

Pageof 2

Frequent Collaborators

4 joint publications

Weiping Jia

2 joint publications

Yuqian Bao

1 joint publications

Dalong Zhu

1 joint publications

Yahao Wang